SLB Hosts Session at SBI 2019

SLB Hosts Session at SBI 2019 meeting

SLB is pleased to expand the society's reach through other related meetings.  The latest addition to this list is an SLB sponsored session at the SBI 2019 meeting LIV Congress of the Brazilian Society of Immunology (SBI) Immunotherapy: Recent Advances and Future for Therapeutic Interventions.  SLB is sponsoring 2 trainee travel awards for the event and also 2 speakers as described below.  JLB will also be featuring a special focus issue on this event.


SLB Sponsored Speakers at SBI 2019:

Sven Brandau, Ph.D., Professor, West German Cancer Center, University Hospital Essen Germany. I am an immunologist and cell biologist by training. After working at the Research Center Borstel and the University of Lübeck, Germany, I accepted a position at the West German Cancer Center and University Hospital in Essen, Germany. My main research interest is immuno-oncology of solid tumors, with a focus on myeloid cells, particularly tumor-associated neutrophils and myeloid-derived suppressor cells (MDSC). I am also engaged in several international activities aimed at standardizing and harmonizing MDSC analysis and research. My laboratory uses in vitro systems, preclinical mouse models, and human translational immuno-oncology studies. Our goal is to decipher how myeloid cells promote cancer progression and to develop immunotherapeutic interventions to target the mechanisms behind this activity.

Jose Conejo-Garcia, M.D., Ph.D., Chair, Department of Immunology, H. Lee Moffitt Cancer Research Institute, and Co-leader, immunology Program, H. Lee Moffitt Cancer Center. The goal of my research program is to identify and target mechanisms governing the balance between immunosuppression and protective immunity in the tumor microenvironment, with an emphasis on the role of cancer-driven pathological myelopoiesis. By combining translational understanding and clinical specimens with mechanistic studies in mouse models, I have worked to elucidate many of the mechanisms driving or blunting protective immunity against ovarian cancer that have been unveiled in recent years, as demonstrated by >100 of recent articles that total >9,000 citations in Scopus. My subsequent independent studies have been funded by federal grants, which support a combination of productive basic and translational researchers in my laboratory, all focused on the immunobiology of cancer.